MOUD Buprenorphine Subli denied as not FDA-approved for this use by Centene?

Mirrors state Medicaid PDLs. Most state Medicaid programs (post-2023 X-waiver removal) allow PCP prescribing without specialist gatekeeping.

MATA Act 2022 / DATA 2000 X-waiver removal — any DEA-registered prescriber may prescribe buprenorphine. ASAM NPG OUD 2020 first-line. SAMHSA TIP 63 supports doses >24 mg for fentanyl-era patients. EPSDT for under-21.

## Why Centene Issued This Denial

A "not FDA-approved" denial for sublingual buprenorphine used as MOUD is nearly always the result of a billing or routing error — not a correct clinical determination. Sublingual buprenorphine products indicated for opioid use disorder have been FDA-approved for many years. When this denial appears, the most common underlying causes are: the product was billed under a code that Centene maps to an unapproved use, the indication entered on the claim does not match the labeled OUD indication, or the reviewer applied a policy for a different buprenorphine formulation.

For Centene Medicaid plans in particular, federal Medicaid policy strongly supports coverage of evidence-based MOUD, which includes sublingual buprenorphine. A "not FDA-approved" denial for a product that is in fact approved creates both a clinical and a regulatory compliance problem for the plan.

## Why This Denial Is Appealable

This denial is overturned by presenting the FDA approval documentation for the specific product alongside a prescriber letter confirming the prescribed use matches the approved indication. MHPAEA parity arguments provide additional leverage.

## Federal Appeal Framework

• Internal appeal (Level 1): File within the deadline in the denial letter. Centene must respond within 30 days (standard) or 72 hours (expedited).
• External review (ACA §2719 / ERISA §503): Available after exhausting internal appeal — generally within four months of the final internal denial.
• Medicaid fair hearing: If this is a Centene Medicaid managed-care plan, a parallel state fair hearing is available and may move faster.
• Expedited review: Request if discontinuation of MOUD would jeopardize health.

## Concrete Appeal Steps

1. Obtain the denial letter's specific reason code and identify the exact product and claim line Centene flagged. 2. Pull the FDA prescribing label for the specific sublingual buprenorphine product — confirm the OUD indication language. 3. Have your prescriber write a letter confirming the product prescribed is FDA-approved for opioid use disorder and that the prescription is for that labeled indication. 4. Include the NDC and product name from the pharmacy label to eliminate any product-identification ambiguity. 5. Submit a MHPAEA argument if Centene cannot demonstrate comparable scrutiny for other chronic disease medications. 6. Escalate to external review or Medicaid fair hearing if the internal appeal fails.

## Documentation to Gather

• FDA prescribing label for the specific product confirming OUD indication
• Prescriber's letter identifying the product by name/NDC and confirming FDA-approved use
• Pharmacy dispensing records confirming the dispensed product
• Claim denial detail (EOB with reason code)
• Diagnosis documentation confirming OUD

## Criteria-Mapping Structure

| Centene "Not FDA-Approved" Criterion | Supporting Evidence | |---|---| | Product is FDA-approved | FDA prescribing label for the specific product | | Prescribed use matches approved indication | Prescriber letter + ICD-10 OUD diagnosis code | | Correct product billed (NDC matches labeled product) | Pharmacy dispensing record + NDC |